Bioassay Screening and Binding Mode Study of Inhibitors Targe-ting at ERK2
Extracellular Signal-Regulated Kinase 2(ERK2)is a key kinase in the occurrence and development of malignant tumors.At present,no drugs targeting ERK2 have been approved for marketing.The purpose of this study is to obtain novel small molecule inhibitors targeting ERK2.Through plasmid construction,protein expression and kinase activity test in vitro,biological activity screening was carried out on the secondary me-tabolites and compounds in the chemical synthesis compound library of Beibu Gulf constructed in our labora-tory.Molecular docking was used to elucidate the binding mode and mechanism of the compounds with ERK2.Finally,5 compounds(named as compound 1-5)with high inhibitory activity of 6-methoxy-erythro-mycin B,isoerythromycin and pyrimidine urea were obtained by screening,and their half-maximal inhibitory concentrations(IC50)were(4.17±1.82),(13.39±0.93),(27.85±2.55),(19.14±1.02)and(8.55±3.72)µmol/L,respectively.Compound 1-5 have inhibitory activity against ERK2 and the hydrogen bond formed between them and residues of LYS-54,MET-108 and GLN-105 in ERK2 are the key factors affecting the sta-bility of the binding.